Процена 99Тцм-ДТПА орбите СПЕЦТ/ЦТ у комбинацији са тестом функције штитне жлезде у лечењу радиоактивног јода И-131 код пацијената са офталмопатијом-хипертиреозом повезаном са штитном жлездом
Sažetak
Objective: Thyroid-associated ophthalmopathy (TAO) is an autoimmune response to inflammation of the thyroid and orbital tissue. This research evaluated the efficacy of 99Tcm-DTPA orbital SPECT/CT combined with thyroid function test in radioactive iodine I-131 (RAI) treatment of TAO-hyperthyroidism.
Methods: We retrospectively studied clinical activity score (CAS), blood thyrotropine (TSH), free triiodothyronine (FT3), free thyroxine (FT4), thickness of extra-ocular muscle (EOM), and uptake rate (UR) of 99Tcm-DTPA orbital SPECT/CT of 43 patients after 6 months of treatment with 20 mCi RAI. Parameters were compared before and after RAI in patients assessed as effectively treated (normal thyroid function or hypothyroidism), and correlations between blood FSH, FT3, FT4, thickness of EOM, and UR were analyzed after treatment.
Results: After RAI, 35 cases (77 eyes, 81.4%) had normal or hypothyroidism and 8 cases (16 eyes, 12.0%) had hyperthyroidism. Compared with the patients who failed treatment, effectively treated patients had lower CAS, FT3, FT4, and UR and higher blood TSH. In patients with effective treatment, UR of the inferior rectus muscle was positively correlated with FT3 and FT4. Adverse RAI outcomes were associated with smoking and higher iodine-thyroid iodine uptake before treatment.
Conclusions: Combined with TSH, FT3, and FT4 levels, the reduction of 99Tcm-DTPA orbital SPECT/CT UR also indicates an improvement in the disease course of patients. The UR of inferior rectus muscle can be an objective index to evaluate the curative effect of TAO patients.
Sva prava zadržana (c) 2024 Li Su, Ping Mi, Wenqiang Niu, Ting Zhou, Wang Yang, Cheng Chen, Chenggang Huang
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.